



For Immediate Release

Symic Bio to Participate in the 2017 East/West CEO Conference

SAN FRANCISCO, Jan. 3, 2017 – Symic Bio, a clinical stage biopharmaceutical company focused on matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will participate in the 2017 East/West CEO Conference on a panel entitled “Global Perspectives on Funding and Innovation.”

Conference details are as follows:

Date: Sunday, Jan. 8, 2017

Time: 7:40 a.m. PST

Location: Four Seasons Hotel, San Francisco

About Symic Bio

Symic Bio is a clinical stage biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

###

Investor Contacts

Gitanjali Jain Ogawa

The Trout Group

(646) 378-2949

gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com

###